User:Mr. Ibrahem/Afatinib

Mr. Ibrahem/Afatinib
Clinical data
Trade names	Gilotrif, Giotrif, Afanix
Other names	BIBW 2992
AHFS/Drugs.com	Monograph
MedlinePlus	a613044
License data	EU EMA: by INN; US DailyMed: Afatinib;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
Drug class	Tyrosine kinase inhibitor
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	95%
Metabolism	CYP not involved
Elimination half-life	37 hours
Excretion	Faeces (85%), urine (4%)
Identifiers
	IUPAC name N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide;
Chemical and physical data
Formula	C24H25ClFN5O3
Molar mass	485.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C\C=C\C(=O)Nc3cc1c(Nc(cc2Cl)ccc2F)ncnc1cc3OC4COCC4;
	InChI InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1 ; Key:ULXXDDBFHOBEHA-CWDCEQMOSA-N ;
	(what is this?) (verify)

Afatinib, sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC).^[2] It is mainly used in advanced cases with a non-resistant epidermal growth factor receptor (EGFR) mutation.^[2] It is taken by mouth.^[2]

Common side effects include diarrhea, rash, mouth inflammation, dry skin, nausea, and itchiness.^[2] Other side effects may include interstitial lung disease, liver problems, gastrointestinal perforation, and corneal inflammation.^[2] Use in pregnancy may harm the baby.^[2] It is a tyrosine kinase inhibitor which blocks a family of proteins known as ErbB.^[3]^[1]

Afatinib was approved for medical use in the United States and Europe in 2013.^[2]^[3] It is on the World Health Organization's List of Essential Medicines as an alternative to erlotinib.^[4] In the United Kingdom 4 weeks costs the NHS about £2,000 as of 2021.^[5] This amount in the United States costs about 9,800 USD.^[6]

References[edit]

^ ^a ^b "Afatinib Monograph for Professionals". Drugs.com. Archived from the original on 10 December 2021. Retrieved 13 January 2022.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Gilotrif (afatinib) tablet, film coated". DailyMed. Boehringer Ingelheim Pharmaceuticals, Inc. 18 October 2019. Archived from the original on 2 February 2014. Retrieved 4 November 2020.
^ ^a ^b "Giotrif". Archived from the original on 22 November 2021. Retrieved 13 January 2022.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1011. ISBN 978-0857114105.
^ "Gilotrif Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 15 January 2021. Retrieved 13 January 2022.